http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A#Head
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A#assertion
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A#provenance
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A#pubinfo
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A#assertion
http://purl.obolibrary.org/obo/DOID_3393
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_3393
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00998
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A#association
http://www.w3.org/2000/01/rdf-schema#label
"Frovatriptan succinate tablets are contraindicated in patients with: Ischemic coronary artery disease (CAD) (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia), or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions ( 5.1 Wolff-Parkinson-White Syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions ( 5.2 History of stroke, transient ischemic attack (TIA), or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [s ee Warnings and Precautions ( 5.4 Peripheral vascular disease [s ee Warnings and Precautions ( 5.5 Ischemic bowel disease [s ee Warnings and Precautions ( 5.5 Uncontrolled hypertension [see Warnings and Precautions ( 5.8 Recent use (i.e., within 24 hours) of another 5-HT 1 [see Drug Interactions ( 7.1 7.2 Hypersensitivity to frovatriptan succinate (angioedema and anaphylaxis seen) [s ee Warnings and Precautions ( 5.9 History of coronary artery disease or coronary artery vasospasm ( 4 Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders ( 4 History of stroke, transient ischemic attack, or hemiplegic or basilar migraine ( 4 Peripheral vascular disease ( 4 Ischemic bowel disease ( 4 Uncontrolled hypertension ( 4 Recent (within 24 hours) use of treatment with another 5-HT 1 4 Hypersensitivity to frovatriptan succinate tablets (angioedema and anaphylaxis seen) ( 4"
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A#association
https://w3id.org/biolink/vocab/relation
https://schema.org/MedicalContraindication
https://identifiers.org/drugbank:DB00998
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A#provenance
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A#pubinfo
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A#sig
http://purl.org/nanopub/x/hasSignature
cdU6ZiV0jP+1Ptbr+tKIJM91MMjvEPZLvMMLNaPjLDUQ32M06+DVV8x/8IrNgyw3Qd3vMLlJwUpOViSwEtQhqiePf0XpMr1wOMOHq2KmIaXkfTz3RAP9rwyLH4noPzpvu+v05dzEJlnA6lf/NxZXgHLDXDOoy9nl/XGrm1vGQ34=
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A
http://purl.org/dc/terms/created
2021-08-23T18:38:13.760+02:00
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAnxcUg66oIDxDtse0FG6ZrnNAo2AVWGwp0yqQNfSFA-A
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY